Restricted accessCase reportFirst published online 2010-06
Posterior Reversible Encephalopathy Syndrome After Intravitreal Bevacizumab Injection in Patient with Choroidal Neovascular Membrane Secondary to Age-Related Maculopathy
The posterior reversible encephalopathy syndrome (PRES), a complex of cerebral disorders including headache, seizures, visual disturbances, is associated with a variety of conditions in which blood pressure rises acutely. Arterial hypertension can occur in systemic administration of bevacizumab. A few cases of systemic injection of bevazicumab-induced PRES have been reported. In this article, we first report on a patient who developed PRES following intravitreal bevazicumab.
RosenfeldP.J., MoshfeghiA.A., PuliafitoC.A.Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg. Lasers Imaging., 36:331–335. 2005.
3.
FungA.E., RosenfeldP.J., ReichelE.The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br. J. Ophthalmol., 90:1344–1349. 2006.
4.
WillettC.G., BoucherY., di TomasoE.et al.Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med., 10:145–147. 2004.
5.
OczanC., WongS.J., HariP.Reversible posterior leukoencephalopathy syndrome and bevacizumab. N. Engl. J. Med., 9:980–982. 2006.
6.
BürkiF., BadieK., BartoliP.et al.Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen. Br. J. Clin. Pharmacol., 65:793–794. 2008.
7.
BakriS.J., SnyderM.R., ReidJ.M.et al.Pharmacokinetics of intravitreal bevacizumab (Avastin)Ophthalmology., 114:855–859. 2007.
8.
RasierR., ArtunayO., YuzbasiogluE.et al.The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension. Eye., 23:1714–1718. 2009.
